Macrophage polarization synergizes with oxaliplatin in lung cancer immunotherapy via enhanced tumor cell phagocytosis

Li, Fēi; Zhou, Xue; Wang, Xue; Xu, Jinhua; Zhang, Qianyun

doi:10.1016/j.tranon.2021.101202

Cited by 12 publications

(7 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment with R848 is effective in various types of cancer, such as breast, pancreatic, and colorectal cancer [ 112 , 115 , 116 ]. Moreover, recent studies focusing on macrophages have highlighted the therapeutic efficacy of R848, either alone or in combination with other drugs, in lung cancer [ 117 , 118 ].…”

Section: The Tlr7/8 Signaling Pathwaymentioning

confidence: 99%

Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives

Sun

Zhang

et al. 2022

Biomark Res

View full text Add to dashboard Cite

Toll-like receptors (TLRs) are a large family of proteins that are expressed in immune cells and various tumor cells. TLR7/8 are located in the intracellular endosomes, participate in tumor immune surveillance and play different roles in tumor growth. Activation of TLRs 7 and 8 triggers induction of a Th1 type innate immune response in the highly sophisticated process of innate immunity signaling with the recent research advances involving the small molecule activation of TLR 7 and 8. The wide range of expression and clinical significance of TLR7/TLR8 in different kinds of cancers have been extensively explored. TLR7/TLR8 can be used as novel diagnostic biomarkers, progression and prognostic indicators, and immunotherapeutic targets for various tumors. Although the mechanism of action of TLR7/8 in cancer immunotherapy is still incomplete, TLRs on T cells are involved in the regulation of T cell function and serve as co-stimulatory molecules and activate T cell immunity. TLR agonists can activate T cell-mediated antitumor responses with both innate and adaptive immune responses to improve tumor therapy. Recently, novel drugs of TLR7 or TLR8 agonists with different scaffolds have been developed. These agonists lead to the induction of certain cytokines and chemokines that can be applied to the treatment of some diseases and can be used as good adjutants for vaccines. Furthermore, TLR7/8 agonists as potential therapeutics for tumor-targeted immunotherapy have been developed. In this review, we summarize the recent advances in the development of immunotherapy strategies targeting TLR7/8 in patients with various cancers and chronic hepatitis B.

show abstract

Section: The Tlr7/8 Signaling Pathwaymentioning

confidence: 99%

Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives

Sun

Zhang

et al. 2022

Biomark Res

View full text Add to dashboard Cite

show abstract

“…On the other hand, several studies have reported that the M2-polarized TAMs contribute to the OXA resistance by suppressing the cancer cell apoptosis (Fu et al, 2019 ; Guo et al, 2017 ; Lan et al, 2021 ). As expected, OXA has demonstrated synergy with R848, a small molecule that converts macrophages from M2 to M1, in cancer treatments (Li et al, 2021 ; Liu et al, 2020 ). Our results showed that the Oxa+ E. coli co-treatment robustly re-polarized the TAMs into the M1 subtype.…”

Section: Discussionmentioning

confidence: 54%

Bacteria colonization in tumor microenvironment creates a favorable niche for immunogenic chemotherapy

Lim,

Lin,

Huang

et al. 2024

EMBO Mol Med

View full text Add to dashboard Cite

The tumor microenvironment (TME) presents differential selective pressure (DSP) that favors the growth of cancer cells, and monovalent therapy is often inadequate in reversing the cancer cell dominance in the TME. In this work, we introduce bacteria as a foreign species to the TME and explore combinatorial treatment strategies to alter DSP for tumor eradication. We show that cancer-selective chemotherapeutic agents and fasting can provide a strong selection pressure against tumor growth in the presence of bacteria. Moreover, we show that an immunogenic drug (oxaliplatin), but not a non-immunogenic one (5-FU), synergizes with the bacteria to activate both the innate and adaptive immunity in the TME, resulting in complete tumor remission and a sustained anti-tumor immunological memory in mice. The combination of oxaliplatin and bacteria greatly enhances the co-stimulatory and antigen-presenting molecules on antigen-presenting cells, which in turn bridge the cytotoxic T cells for cancer-cell killing. Our findings indicate that rational combination of bacterial therapy and immunogenic chemotherapy can promote anticancer immunity against the immunosuppressive TME.

show abstract

“…39 R848 is a potent TLR7/8 agonist that can shift the polarization of TAMs towards the M1 phenotype. 40 Similarly, in IL-4 induced M2 polarized J774.A macrophages, mLAPMi-R848 significantly increased the CD80 marker, indicating that macrophages were polarized to M1 inflammatory macrophages (Fig. S10 †).…”

Section: Paper Biomaterials Sciencementioning

confidence: 84%

A sugar modified amphiphilic cationic nano-adjuvant ceased tumor immune suppression and rejuvenated peptide vaccine induced antitumor immunity in cervical cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

Macrophage polarization synergizes with oxaliplatin in lung cancer immunotherapy via enhanced tumor cell phagocytosis

Abstract: Highlight LLC cells pretreated with OXA were more prone to be phagocytized by M1 than M2 macrophages. M2 repolarized to M1 by R848 in vitro showed enhanced phagocytic ability to OXA-treated LLC cells. Macrophage polarization from pro-tumor M2 to anti-tumor M1 synergizes with OXA.

Cited by 12 publications

References 36 publications

Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives

Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives

Bacteria colonization in tumor microenvironment creates a favorable niche for immunogenic chemotherapy

A sugar modified amphiphilic cationic nano-adjuvant ceased tumor immune suppression and rejuvenated peptide vaccine induced antitumor immunity in cervical cancer

Contact Info

Product

Resources

About